loadpatents
Patent applications and USPTO patent grants for MEDIBIOFARMA, S.L..The latest application filed is for "new n-benzyl-2-phenoxybenzamide derivatives as prostaglandin e2 (pge2) receptors modulators".
Patent | Date |
---|---|
New N-benzyl-2-phenoxybenzamide Derivatives As Prostaglandin E2 (pge2) Receptors Modulators App 20220117962 - Palomino Laria; Julio Castro ;   et al. | 2022-04-21 |
Benzamide derivatives as PPAR-gamma modulators Grant 11,267,808 - Castro Palomino Laria , et al. March 8, 2 | 2022-03-08 |
Heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and/or 2(HDAC1-2) Grant 11,241,428 - Castro Palomino Laria , et al. February 8, 2 | 2022-02-08 |
New Benzamide Derivatives As Ppar-gamma Modulators App 20210171511 - CASTRO PALOMINO LARIA; Julio ;   et al. | 2021-06-10 |
New Heteroaryl Amide Derivatives As Selective Inhibitors Of Histone Deacetylases 1 And/or 2 (hdac1-2) App 20200138808 - CASTRO PALOMINO LARIA; Julio ;   et al. | 2020-05-07 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.